Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Trummel

Optometrist Lawrence, KS Doctor of Optometry

NPI 1003813809 CMS profile 272286

3111 W 6Th St, Lawrence, KS 66049

Open in the dashboard

General payments

$2,128

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Trummel of Lawrence, KS is reported in the CMS Open Payments database as having received $2,128 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $322 15
2024 General $286 12
2023 General $416 14
2022 General $269 14
2021 General $253 13
2020 General $308 14
2019 General $274 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Trummel
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Kevin Trummel were reported at $322. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Kevin Trummel Optometrist median Middle half National median
2019 $274 $159 $67–$371 $163
2020 $308 $72 $29–$165 $114
2021 $253 $125 $46–$292 $132
2022 $269 $162 $66–$374 $149
2023 $416 $177 $72–$406 $160
2024 $286 $188 $77–$427 $164
2025 $322 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Vision Care, Inc. $1,485 69 payments
  2. Bausch & Lomb Americas Inc. $256 13 payments
  3. RxSight Inc $125 1 payment
  4. Alcon Vision LLC $91 5 payments
  5. CooperVision Inc. $53 2 payments
  6. Sun Pharmaceutical Industries Inc. $49 2 payments
  7. Shire North American Group Inc $22 1 payment
  8. Allergan Inc. $18 1 payment
  9. Oyster Point Pharma, Inc. $15 1 payment
  10. Kala Pharmaceuticals, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,128 96 payments
Products named General payments · program years 2019–2025
  1. Acuvue $1,137 55 payments
  2. INFUSE $275 14 payments
  3. RXSIGHT CONTACT LENS $125 1 payment
  4. RXSIGHT INJECTOR CARTRIDGE $125 1 payment
  5. RXSIGHT INJECTOR HANDPIECE $125 1 payment
  6. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $125 1 payment
  7. RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL) $125 1 payment
  8. Cequa $49 2 payments
  9. Precision7 $38 2 payments
  10. Clariti Contact Lens $36 1 payment
  11. Other $140 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

308

Median for Optometry: 120

Drug cost

$47,026

Median for Optometry: $8,864

Branded share of claims

28.9%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 20 $22,192
Lumigan Bimatoprost Brand 53 $21,563
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 16 $1,912
Latanoprost Generic 89 $349
Prednisolone Acetate Generic 14 $276
Timolol Maleate Generic 65 $253
Doxycycline Hyclate Generic 13 $186
Brimonidine Tartrate Generic 20 $157
Ofloxacin Generic 18 $138

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$54,831

Medicare's payments for the services billed

Medicare patients

649

Average age 72

Services billed

876

410 women, 239 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 41%
Diabetes 20%
Depression 20%
Ischemic heart disease 18%
Osteoporosis 16%
Atrial fibrillation 13%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record